- Home
- ESNT vs DNTH Comparison
ESNT vs DNTH Comparison
Compare ESNT & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESNT | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.5B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ESNT | DNTH |
|---|---|---|
| Price | $68.90 | $105.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $67.29 | ★ $121.00 |
| AVG Volume (30 Days) | 518.7K | ★ 652.5K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 0.73 | N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $1,260,935,000.00 | $2,036,000.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $3.37 | $29.48 |
| P/E Ratio | $17.81 | ★ N/A |
| Revenue Growth | ★ 1.45 | N/A |
| 52 Week Low | $55.34 | $23.39 |
| 52 Week High | $70.37 | $117.88 |
Technical Indicators
Market Signals| Indicator | ESNT | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 49.24 |
| Support Level | $67.89 | $100.00 |
| Resistance Level | $70.19 | $116.21 |
| Average True Range (ATR) | 1.06 | 4.39 |
| MACD | -0.09 | -0.94 |
| Stochastic Oscillator | 67.71 | 24.17 |
Price Performance
Historical ComparisonAbout ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.